Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280791 | 0.91 | POLB (0.39) | POLBDDR1PTGDR2AGPAT2 | |
| SCHEMBL10280988 | 0.89 | POLB (0.49) | POLBDDR1PTGDR2AGPAT2PDE10A | |
| SCHEMBL15426411 | 0.89 | POLB (0.41) | POLBDDR1AGPAT2PDE10AS1PR1 | |
| SCHEMBL17058744 | 0.87 | POLB (0.33) | POLB | |
| SCHEMBL15412561 | 0.87 | POLB (0.40) | POLBDDR1PTGDR2AGPAT2PDE10A | |
| SCHEMBL15868307 | 0.84 | POLB (0.45) | POLBCRHR1 | |
| SCHEMBL10280994 | 0.83 | KDM4E (0.36) | POLBPDE10A | |
| SCHEMBL15426442 | 0.82 | POLB (0.39) | POLBDDR1PTGDR2S1PR1 | |
| SCHEMBL10280699 | 0.81 | POLB (0.48) | POLBDDR1AGPAT2 | |
| SCHEMBL10281056 | 0.81 | POLB (0.48) | POLBDDR1AGPAT2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278983-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-28 | — | — | US | disclosed |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8853238-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | NR4A1, NR2C2, NR0B1 | POLB 4715/4885DDR1 3079/4885PTGDR2 2655/4885 |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SFXN1, OSR1, PIR | POLB 4471/4885DDR1 2720/4885PTGDR2 4472/4885 |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | NR4A1, NR2C2, NR0B1 | POLB 4737/4885DDR1 3074/4885PTGDR2 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.